Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN63,1863,22-1,36
Msft0,22
Nokia3,2013,328-3,53
IBM0,32
Mercedes-Benz Group AG73,4273,440,36
PFE-0,79
19.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.03.2024
BioAlliance (C4X.F, Frankfurt)
Závěr k 18.3.2024 Změna (%) Změna (EUR) Objem obchodů (EUR)
0,096 0,00 0,00 234
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.03.2024
Popis společnosti
Obecné informace
Název společnostiValerio Therapeutics SA
TickerALVIO
Kmenové akcie:Ordinary Shares
RICALVIO.PA
ISINFR0010095596
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.06.2023
Počet zaměstnanců k 30.06.2023 39
Akcie v oběhu k 30.06.2023 154 077 113
MěnaEUR
Kontaktní informace
Ulice49 boulevard du General Martial Valin
MěstoPARIS
PSČ75015
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 145 587 600
Fax33145580881

Business Summary: Valerio Therapeutics SA formerly Onxeo SA is a France-based clinical-stage biotechnology company. The company targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). It aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Valerio Therapeutics SA revenues was not reported. Net loss increased 2% to EUR11.6M. Higher net loss reflects R&D costs increase of 37% to EUR5.6M (expense), Labor & Related Expenses in SGA increase of 15% to EUR5.1M (expense), Other operating income decrease from EUR385K (income) to EUR0K. Basic Earnings per Share excluding Extraordinary Items remained flat at -EUR0.10.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 19.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Executive DirectorShefali Agarwal4907.04.202207.04.2022